
Smith & Nephew PLC (LSE:SN) drew a cautious assessment from Jefferies on Friday, with the broker maintaining its 'buy' rating despite investor scepticism over execution and a reduced financial year 20
SharkNinja NYSE: SN reported second-quarter 2026 results marked by accelerating sales growth, higher adjusted earnings and a raised full-year outlook, as the company cited broad demand across domestic

Smith & Nephew PLC (LSE:SN) has cut its full-year revenue growth forecast after weakness in its US orthopaedics and wound care businesses in the second quarter. The FTSE 100 medical technology group n